Kenneth R. Hande

8.8k total citations · 3 hit papers
128 papers, 6.8k citations indexed

About

Kenneth R. Hande is a scholar working on Oncology, Molecular Biology and Epidemiology. According to data from OpenAlex, Kenneth R. Hande has authored 128 papers receiving a total of 6.8k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Oncology, 43 papers in Molecular Biology and 37 papers in Epidemiology. Recurrent topics in Kenneth R. Hande's work include Lung Cancer Research Studies (40 papers), Neuroendocrine Tumor Research Advances (33 papers) and Cancer therapeutics and mechanisms (30 papers). Kenneth R. Hande is often cited by papers focused on Lung Cancer Research Studies (40 papers), Neuroendocrine Tumor Research Advances (33 papers) and Cancer therapeutics and mechanisms (30 papers). Kenneth R. Hande collaborates with scholars based in United States, Sweden and Malaysia. Kenneth R. Hande's co-authors include F. Anthony Greco, John D. Hainsworth, David H. Johnson, Bruce A. Chabner, William J. Stone, George C. Garrow, Samuel A. Jacobs, Ronald G. Stoller, Steven A. Rosenberg and S N Wolff and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of Clinical Oncology.

In The Last Decade

Kenneth R. Hande

126 papers receiving 6.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Etoposide: four decades of development of a topoisomerase II inhibitor

1998 770 citations Kenneth R. Hande European Journal of Cancer profile →
Severe allopurinol toxicity

1984 520 citations Kenneth R. Hande et al. profile →
Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules

2009 397 citations Kenneth R. Hande et al. Journal of Clinical Oncology profile →

Peers

Kenneth R. Hande

ONCOL

PRM

EPIDE

SURGE

Étienne Chatelut France

Philip S. Schein United States

Tsutomu Nobori Japan

Richard J. Jones United States

Martin H. Cohen United States

Keith R. McCrae United States

Xavier Filella Spain

Adrian C. Newland United Kingdom

Esteban Cvitkovic France

Howard S. Höchster United States

Étienne Chatelut France

Kenneth R. Hande

2.6k ×0.9

ONCOL

1.8k ×0.7

1.0k ×0.6

PRM

605 ×0.5

EPIDE

637 ×0.8

SURGE

Citations per year, relative to Kenneth R. Hande Kenneth R. Hande (= 1×) peers Étienne Chatelut

Countries citing papers authored by Kenneth R. Hande

Since Specialization

Citations

This map shows the geographic impact of Kenneth R. Hande's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenneth R. Hande with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenneth R. Hande more than expected).

Fields of papers citing papers by Kenneth R. Hande

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenneth R. Hande. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenneth R. Hande. The network helps show where Kenneth R. Hande may publish in the future.

Co-authorship network of co-authors of Kenneth R. Hande

This figure shows the co-authorship network connecting the top 25 collaborators of Kenneth R. Hande. A scholar is included among the top collaborators of Kenneth R. Hande based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenneth R. Hande. Kenneth R. Hande is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mignemi, Nicholas A., Doha Itani, Vicki L. Keedy, et al.. (2012). Signal transduction pathway analysis in desmoid‐type fibromatosis: Transforming growth factor–β, COX2 and sex steroid receptors. Cancer Science. 103(12). 2173–2180. 29 indexed citations

Cates, Justin, Jennifer O. Black, Doha Itani, et al.. (2012). Signal transduction pathway analysis in fibromatosis: receptor and nonreceptor tyrosine kinases. Human Pathology. 43(10). 1711–1718. 4 indexed citations

Nygren, Peter, Kenneth R. Hande, Kevin J. Petty, et al.. (2005). Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemotherapy and Pharmacology. 55(6). 609–616. 56 indexed citations

Martincic, Danko & Kenneth R. Hande. (2005). Topoisomerase II inhibitors. 101–121. 20 indexed citations

Choy, H., et al.. (2000). A Phase I Trial of Outpatient Weekly Docetaxel and Concurrent Radiation Therapy for Stage III Unresectable Non–Small-Cell Lung Cancer: A Vanderbuilt Cancer Center Affiliate Network (VCCAN) Trial. Clinical Lung Cancer. 1. S27–S31. 20 indexed citations

Nicholson, Brenda P., et al.. (2000). Paclitaxel, 5-Fluorouracil, and Leucovorin (TFL) in the Treatment of Metastatic BreastCancer. Clinical Breast Cancer. 1(2). 136–143. 7 indexed citations

Grunberg, Steven M., John Crowley, Kenneth R. Hande, et al.. (1999). Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic study. Cancer Chemotherapy and Pharmacology. 44(6). 461–468. 15 indexed citations

Hande, Kenneth R.. (1998). Etoposide: four decades of development of a topoisomerase II inhibitor. European Journal of Cancer. 34(10). 1514–1521. 770 indexed citations breakdown →

Hande, Kenneth R.. (1998). Clinical applications of anticancer drugs targeted to topoisomerase II. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression. 1400(1-3). 173–184. 214 indexed citations

10.

Basinger, Mark A., et al.. (1996). Prevention of cisplatin nephrotoxicity by exogenous atrial natriuretic peptide. Toxicology. 106(1-3). 159–166. 2 indexed citations

11.

Ryan, Michael P., et al.. (1995). The Role of the Renin-Angiotensin System in Cisplatin Nephrotoxicity. Renal Failure. 17(6). 665–674. 29 indexed citations

12.

Anthony, Lowell, David H. Johnson, Kenneth R. Hande, et al.. (1993). Somatostatin Analogue Phase I Trials in Neuroendocrine Neoplasms. Acta Oncologica. 32(2). 217–223. 91 indexed citations

13.

Hande, Kenneth R., Mary G. Krozely, F. Anthony Greco, John D. Hainsworth, & David H. Johnson. (1993). Bioavailability of low-dose oral etoposide.. Journal of Clinical Oncology. 11(2). 374–377. 119 indexed citations

14.

Johnson, David H., Russell F. DeVore, F. Anthony Greco, et al.. (1992). Carboplatin plus oral etoposide in the management of advanced, non-small cell lung cancer: preliminary results of a Vanderbilt trial.. PubMed. 19(1 Suppl 2). 50–6. 5 indexed citations

15.

Murphy, Patrick B., et al.. (1992). Prolonged Administration of Oral Etoposide plus Cisplatin in Extensive Stage Small Cell Lung Cancer. Oncology. 49(1). 34–39. 4 indexed citations

16.

Johnson, David H., et al.. (1992). Carboplatin plus Oral Etoposide in the Management of Unresectable Non-Small Cell Lung Cancer. Oncology. 49(1). 57–62. 9 indexed citations

17.

Greco, F. Anthony, et al.. (1989). Combined small-cell and non-small-cell lung cancer.. Journal of Clinical Oncology. 7(5). 607–612. 109 indexed citations

18.

List, Alan F., J P Greer, Richard S. Stein, et al.. (1988). Non-Hodgkin's lymphoma of the gastrointestinal tract: an analysis of clinical and pathologic features affecting outcome.. Journal of Clinical Oncology. 6(7). 1125–1133. 72 indexed citations

19.

Drake, J C, Kenneth R. Hande, Richard W. Fuller, & Bruce A. Chabner. (1980). Cytidine and deoxycytidylate deaminase inhibition by uridine analogs. Biochemical Pharmacology. 29(5). 807–811. 16 indexed citations

20.

Hande, Kenneth R., et al.. (1977). Effect of hydration on plasma-methotrexate levels.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 61(7). 1393–6. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact